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Abstract
B ackground: The T cell attracting chemokine CCL18 is produced by antigen presenting cells and 
a role for CCLI8 has been suggested in the pathogenesis of a variety of diseases. Rheumatoid 
arthritis (RA) is one of these conditions, in which abundant CCL18 production is present. Although 
Th2 cytokines and IL-10 are known to have an effect on CCLI8 production, there are several gaps 
in our knowledge regarding the exact regulation of CCLI8 secretion, both in general and in RA. In 
this study we provide new insights in the regulation of CCLI8 secretion by monocytes and 
dendritic cells.
Results: In contrast to  a large panel of pro-inflammatory stimuli (IL-I ß, TNF-a, IL-10, IL-13, IL-15, 
IL-17, IL-I8, IFN-y), T cell mimicking molecules (RANKL, CD40L) o r TLR driven maturation, the 
anti-inflammatory IL-I0 strongly stimulated DC to  secrete CCLI8. On freshly isolated monocytes, 
CCLI8 secretion was induced by IL-4 and IL-I3, in strong synergy with IL-I0. This synergistic effect 
could already be observed after only 24 hours, indicating that not only macrophages and dendritic 
cells, but also monocytes secrete CCLI8 under these stimulatory conditions. A high CCLI8 
expression was detected in RA synovial tissue and incubation of monocytes with synovial fluid from 
RA patients clearly enhanced the effects of IL-4, IL-I3 and IL-I0. Surprisingly, the effect of synovial 
fluid was not driven by IL-I0 of IL-I3, suggesting the presence of another CCLI8 inducing factor in 
synovial fluid.
C onclusion: In summary, IL-I0 synergistically induces CCLI8 secretion in combination with IL-4 
of IL-I3 on monocytes and monocyte derived cells. The effects of IL-I4, IL-I3 and IL-I0 are strongly 
enhanced by synovial fluid. This synergy may contribute to  the high CCLI8 expression in RA.
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Background
Rheum atoid arthritis (RA) is a chronic au toim m une dis­
ease th a t is m ainly characterized by inflam m ation o f  the 
synovial tissue (ST), leading to  cartilage and bone destruc­
tion. Influx o f different inflam m atory cells in to  the ST and 
enhanced production  o f cytokines and chem okines are all 
well know n features o f RA. Chem okines are small pro­
teins tha t act as key players in  the chem o-attraction o f  dif­
ferent leucocytes and perform  their chemo-attractive task 
through interaction w ith their receptor on  the target cell. 
Several chem okines have been show n to be abundantly  
present in  RA ST at highly strategic sites [1-3], w hich sug­
gests a role for these chem okines in  the pathogenesis of 
RA. In this respect, chem okines could be regarded as 
prom ising therapeutic targets in  RA. This concept has 
already been translated to  the clinic, since the blockade of 
C C hem okine Receptor 1 (CCR1) has recently been 
show n to be clinically effective in  the treatm ent o f RA [4].
Antigen presenting cells (APC), such as dendritic cells 
(DC) and  m acrophages (M®), are generally accepted as 
critical m ediators in  the com plex pathogenesis o f RA [5­
7]. APC produce a m ultitude o f chem okines tha t attract 
specific T cell subsets. Such chem okines are likely to  play 
a critical role in  the regulation o f im m une responses, since 
they orchestrate the spatial and  tem poral interaction 
betw een APC and T cells, w hich determ ines the fate and 
nature o f the im m une response. Evidence for this concep­
tual framework came recently from  the observation that 
blocking APC-T cell interactions using CTLA4-Ig led to  a 
significant reduction o f disease activity in  RA [8]. Several 
chem okines orchestrate the attraction o f T cells toward 
DC. It is tem pting to  speculate th a t interfering w ith these 
chem okines w ould lead to sim ilar effects on  disease activ­
ity as the direct blockade o f T-cell DC interaction. O f this 
group o f T- cell attracting chem okines, CCL18 and 
CXCL16 recently came ou t as potentially interesting tar­
gets in  RA from  previous research by our group and others 
[9-13].
CC chem okine ligand 18 (CCL18, also DC-CK-1, PARC, 
AMAC-1) was first identified as a naïve T cell attracting 
chem okine [14-16]. Next to  chem o-attraction, CCL18 
plays a role in  stim ulation o f collagen production  by 
fibroblasts [17]. Despite num erous attem pts to identify its 
receptor, CCL18 is still an orphan  chemokine. In vivo, 
CCL18 expression was first found in  high quantities in  the 
lung, w hich is caused by the abundan t expression by alve­
olar m acrophages [15]. In vitro, DC and  M® have been 
identified as CCL18 producers [14-16,18,19]. To date, a 
substantial am ount o f data points tow ard the enrichm ent 
o f DC and M® in  the synovial tissue w hich likely to  be 
responsible for the increased levels o f  CCL18 in  RA syno­
vial tissue and  synovial fluid (SF) com pared w ith that 
from  healthy individuals [18,20]. In this line, CCL18 has
been identified as a clinical m arker in  Gaucher's disease, a 
condition  in  w hich M® activation is likely to  play a role 
in  the pathogenesis [21,22]. In addition, a role for CCL18 
has been suggested in  a large variety o f diseases, such as 
systemic sclerosis and acute lym phoblastic leukaem ia 
[23,24]. In RA, we recently found tha t circulating CCL18 
levels are elevated com pared w ith controls and correlated 
w ith disease activity (van Lieshout et al. m anuscript sub­
m itted). Moreover, CCL18 mRNA expression by DC from 
RA patients was show n to be higher than  by DC from 
healthy controls, w hich could be influenced by blockade 
o f  TNF-a [10,13]. The exact regulation o f CCL18 protein 
secretion however is com plicated and the studies pub ­
lished thus far have led to  controversial results [18,19,25­
27], as elegantly reviewed by Schutyser et al [28].
In order to clarify the m echanism  o f CCL18 expression 
and secretion in  RA, we investigated the role o f  a large 
panel o f inflam m atory m ediators know n to play a role in  
the disease process o n  CCL18 secretion. Here we show 
th a t CCL18 secretion by m onocytes and  DC is regulated 
by synergistic effects betw een IL-4/IL-13, IL-10 and  RA SF, 
whereas pro-inflam m atory cytokines and Toll-like recep­
tor (TLR) ligands did n o t have any influence on  CCL18 
secretion. These data add novel inform ation to  the puzzle 
o f  increased CCL18 expression in  RA.
Results
IL-10 strongly enhances C C L I8  production by m oD C  while 
m aturation  and p ro-in flam m atory m ediators do not
First we investigated w hether several m ediators tha t are 
know n to be im portan t in  RA were able to  enhance CCL18 
production  by MoDC. In line w ith previous studies, 
unstim ulated  im m ature DC (iDC) produced significant 
am ounts o f CCL18 [19]. Interestingly, incubation w ith 
TNF-a, IL-1 ß, IL-13, IL-15, IL-17, IL-18 and IFN-y did n o t 
stim ulate CCL18 secretion w hen added to  day 6 iDC (n  = 
6). In contrast, the anti-inflam m atory IL-10 strongly 
induced CCL18 production by iDC (p = 0.03) (figure 1a). 
Next we tested w hether factors well know n to induce m at­
u ration  or T cell m im icking could induce CCL18 produc­
tion. These experim ents dem onstrated th a t LPS, CD40L 
and RANKL did n o t enhance CCL18 production (n  = 3) 
(figure 1b). Recent studies dem onstrated tha t o ther TLR 
pathways than  TLR4 are all capable o f inducing DC m atu­
ration, b u t have different effects on  cytokine production  
[29-31]. However, stim ulation o f  TLR2 (pam 3cys), TLR3 
(poly (i:c)), TLR4 (LPS) or TLR7/8 (R848) d id  n o t sort any 
effect on  CCL18 secretion (n  = 6) (figure 1c), whereas they 
d id  elicit a p o ten t cytokine response [31]. Since IL-13 is 
m ore abundantly  present in  RA than  IL-4 and  since some 
conflicting results have been published on  CCL18 produc­
tion  induced by LPS w hen DC were cultured w ith IL-13 vs. 
IL-4, we com pared these culture m ethods (n  = 6). In bo th  
the IL-4 and  IL-13 cultures, IL-10 strongly induced CCL18
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Figure 1
IL-10 induces CCL18 sec re tio n  by m o n o cy te  derived  d en d ritic  cells. Panel A depicts CCLI8 secretion by MoDC (cul­
tured with IL-4 and GM-CSF) upon stimulation with TNF-a, IL-Iß, IL-I0, IL-I3, IL-I5, IL-I7, IL-I8 (all 20 ng/ml) and IFN-y (I0 
ng/ml) (n = 6). Panel B depicts Cc LI8 secretion by MoDC upon stimulation with LPS (2 |lg/ml), CD40L or RANKL (20 ng/ml) 
(n = 3). Panel C depicts CCLI8 secretion upon stimulation upon TLR2 (pam3cys, I0 |lg/ml), TLR3 (poly (i:c), 25 |lg/ml), TLR4 
(LPS, 2 |lg/ml) or TLR7/8 (R848, I |lg/ml) mediated stimulation (n = 5) In all experiments, a direct comparison was made with 
unstimulated cells. The bars represent the mean (± SEM) CCLI8 secretion in pg/ml. * represents a p-value of <0,05 (Wilcoxon 
Signed Rank test)
(p = 0.03 for b o th  IL-4 and  IL-13 culture), while LPS again 
did n o t (figure 2). In addition, IL-10 in  com bination  with 
LPS was n o t significantly different from  IL-10 alone (fig­
ure 2). Also co-stim ulation w ith LPS and  the cytokines 
tested (as in  figure 1) did n o t sort any effect on  CCL18 
secretion (data n o t shown).
IL-10 acts in synergy w ith IL-4/L-13 in prom oting CCL18  
production by monocytes
MoDC and alternatively activated M® (AaM®) [32,33] 
are know n to produce CCL18. Both these cell types origi­
nate from  CD14+ m onocytes and depend on  IL-4 or IL-13 
(in  com bination  w ith GM-CSF for MoDC) for their differ­
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F ig u re 2
S im ilar p a tte rn  o f CCL18 p ro d u c tio n  by IL-4 vs. IL-13 c u ltu red  m o n o cy te  derived  d en d ritic  cells. Immature 
MoDC were initially cultured with either IL-4 or IL-I3, in combination with GM-CSF. On day 6, these immature DC were 
stimulated for 48 hours with IL-I0 (20 ng/ml), LPS (2 |lg/ml) or both. The bars represent the mean (± SEM) CCLI8 (pg/ml) 
production/ml of 6 individual experiments. * represents a p-value of <0,05 (Wilcoxon Signed Rank test)
entiation. To determ ine w hether CCL18 secretion by mye­
loid cells is dependent on  these cytokines, monocytes 
were freshly isolated and  stim ulated w ith GM-CSF, IL-4, 
IL-13 and  IL-10 alone or in  com binations (n  = 6). Even 
after 6 days, unstim ulated  and  GM-CSF treated m o n o ­
cytes/macrophages did n o t secrete CCL18, whereas bo th  
IL-4 and IL-13 stim ulation resulted in  a clear secretion of 
CCL18, w hich is in  line w ith previous findings on  AaM® 
[16]. Interestingly, stim ulation w ith IL-10 alone only had 
a m inim al effect on  CCL18 production  by these m o n o ­
cytes/macrophages. W hen IL-10 was provided together 
w ith IL-4 or IL-13, this resulted in  3- and 2-fold increase 
in  CCL18 secretion respectively (figure 3). Interestingly, 
already in  low concentrations, IL-10 had  its synergistic 
effect w ith IL-4 (figure 4a). In order to rule ou t effects of 
adherence, we cultured CD14+ m onocytes/m acrophages 
for three days in  teflon bags [34] and in  ro tation  discs 
[35]. The m orphology o f these cells was com parable with 
freshly isolated m onocytes according to  their forward/side 
scatter pattern  (data n o t shown). In b o th  cultures, IL-4 did 
still induce CCL18 production in  the same way as the cul­
tures in  24-wells plates (figure 4b). As a p ro o f o f principle, 
we next tested w hether the synergy betw een IL-4/IL-13 
and IL-10 could already be observed after only 24 hours. 
Intriguingly, we could indeed observe a clear CCL18 secre­
tion  after 24 hours u p o n  stim ulation o f freshly isolated 
m onocytes w ith IL-4/IL-13 and IL-10, whereas stim ula­
tion  with IL-4, IL-13 or IL-10 alone did only result in  a
m inor or even undetectable CCL18 secretion (n  = 3) (fig­
ure 4c). Since IL-10 appeared to  synergize w ith IL-4 and 
IL-13, we investigated w hether these cytokines could up- 
regulate each other's receptors, possibly resulting in  
enhanced signaling. This was n o t the case; IL-10 did n o t 
u p  regulate either the IL-4/IL-13 com m on receptor IL- 
4Ra1 or the specific IL-13Ra2. Furthermore, IL-4 had  no 
effects on  IL-10Ra (data n o t shown).
RA synovial fluid  enhances CCL18 secretion independently  
o f  IL-10 and IL-13
We and  others dem onstrated CCL18 expression in  RA ST 
in  the lining and the peri-vascular regions [10,20]. In fig­
ure 5, we show a high CCL18 expression in  RA synovial 
tissue (figure 5a,b,c), w hich was preferentially located in  
b o th  the synovial lining layer and  the peri-vascular 
regions. Intriguingly, CCL18 was also expressed in  control 
synovial tissue, although n o t as abundan t as in  RA ST (fig­
ure 5d,e,f). Notably, som e parts o f  the sections were even 
negative for CCL18, w hich is in  sharp contrast w ith RA. In 
order to  explain the abundan t CCL18 expression in  RA, 
we tested w hether incubation w ith RA SF could induce 
CCL18 production  on  m onocytes/m acrophages. Since RA 
SF itself contains CCL18 [18,20], we cultured freshly iso­
lated m onocytes for 3 days in  the presence o f SF, washed 
the cells and  cultured on  for another 3 days in  the absence 
o f  RA SF (n  = 6). Firstly, this pre-incubation w ith RA SF 
resulted in  m arked CCL18 production (m ean 676 (± 151)
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F ig u re3
Synergistic  e ffec t on CCL18 sec re tio n  by m o n o cy tes  
upon stim u la tio n  w ith  IL-4/IL-13 in co m bina tion  w ith 
IL-10. MACS isolated monocytes were cultured for 6 days 
and stimulated on day I with IL-4 (500 U/ml), IL-I3 (20 ng/ 
ml), IL-I0 (20 ng/ml) o r a combination of the cytokines. The 
bars represent the mean (± SEM) CCLI8 (pg/ml) of 6 individ­
ual experiments. In all experiments, a direct comparison was 
made with with unstimulated cells. ND = not detectable. * 
represents a p-value of <0,05 (Wilcoxon Signed Rank test)
pg/m l) (figure 6b). Secondly, culture o f  freshly isolated 
m onocytes in  the presence o f RA SF, resulted in  a 9- and 
10-fold increase in  CCL18 secretion u p o n  stim ulation 
w ith IL4/IL-13 respectively and a 22-fold increase com ­
pared w ith IL-10 alone (figure 6a). Intriguingly, this syn­
ergistic effect w ith IL-4, IL-13 and  IL-10 could still be 
observed after 3 days o f culture in  the com plete absence of 
RA SF (figure 6b), indicating tha t the cell does n o t require 
a continuous stim ulation in  order to  secrete CCL18. To 
exclude intrinsic differences betw een m onocytes/m acro­
phages from  RA patients and controls may contribute to 
the effects on  CCL18 secretion, we tested w hether m o n o ­
cytes/macrophages from  RA patients (n  = 3) responded 
differently to  com binations o f IL-4, IL-13, IL-10 and SF. 
No difference in  the CCL18 secretion pattern  was 
observed betw een m onocytes/m acrophages o f healthy 
controls and RA patients u p o n  these stim uli (data no t 
shown), ruling ou t intrinsic differences in  m onocytes in  
RA tha t affect CCL18 secretion.
Since the synergy caused by RA SF appeared sim ilar to  the 
synergy betw een cytokines we already observed (figure 4), 
we tested w hether IL-10 an d /o r IL-13, bo th  present in  RA 
SF, were responsible for this phenom enon  by blocking 
these cytokines w ith neutralizing antibodies. The potency 
o f these antibodies was first tested by determ ining their 
ability to  inh ib it the synergistic CCL18 secretion up o n  
stim ulation w ith a com bination o f  IL-10 and  IL-4/IL-13.
F ig u re 4
Synergistic  CCL18 p ro d u c tio n  by m o n o cy tes  upon 
stim u la tio n  w ith  IL-4 and  IL-10 can be induced rap ­
idly and  by low  co n c e n tra tio n s  of IL-10. Panel A depicts 
CCLI8 secretion by monocytes upon stimulation with differ­
ent doses of IL-I0 in the presence of IL-4. Panel B represents 
CCLI8 secretion by monocytes that were cultured for three 
days in the presence o r absence of IL-4 in teflon bags o r rota­
tion discs to  prevent adherence. Panel C depicts CCLI8 
secretion by monocytes that were cultured for 24 hours 
with no stimulation or in the presence of IL-4, IL-I 3, IL-I0 or 
a combination of IL-4/IL-I3 with IL-I0. The bars in panel A 
and B represent the mean CCLI8 (pg/ml) of duplicates of I 
individual experiment and panel C shows the mean (± SEM) 
of 3 separate experiments. ND = not detectable
A ddition o f anti-IL-10 resulted in  a 73% inh ib ition  o f the 
synergy betw een IL-4 and  IL-10 and anti IL-13 completely 
abrogated the synergistic effect o f IL-13 w ith IL-10 (figure 
6c). Unexpectedly however, blockade o f  IL-10 or IL-13 in
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Figure 5
CCL18 exp ression  in no rm al and  RA synovial tissue. Panel A and B depict 2 sections of control synovium, where 
CCLI8 expression is expressed in parts of the lining and some perivascular regions. Panel D and E depict 2 representative syn­
ovial sections from RA where CCLI8 is present in the lining and perivascular regions. Panel C and F represent isotype controls 
on RA synovium and that from healthy individuals respectively.
SF in  the presence o f IL-4 or IL-13 and  IL-10 respectively 
did n o t inh ib it the synergy betw een these cytokines and 
SF (figure 6a&b), suggesting th a t SF contains a yet un iden ­
tified factor th a t triggers CCL18 secretion.
Discussion
In this study, we add new pieces to  the com plicated puzzle 
o f CCL18 regulation in  RA. Firstly, we dem onstrate that 
CCL18 production  can be induced by IL-4, IL-13 and  IL- 
10 in  m onocyte derived cells. Secondly, we show th a t a 
large panel o f pro-inflam m atory stim uli and  TLR m edi­
ated signals leading to  DC m aturation  are o f  no  influence 
on  CCL18 production. Thirdly, IL-10 only induces a 
m inor CCL18 secretion, b u t acts in  synergy w ith b o th  IL- 
4 and  IL-13 on  m onocytes and  m onocyte derived cells. 
Finally, we provide evidence th a t RA SF is able to  induce 
CCL18 secretion in  strong synergy w ith IL-4, IL-13 and  IL- 
10, w hich could n o t be inhibited  by a blockade o f  IL-10 
and IL-13.
CCL18 can be produced by MoDC as well as by certain 
types o f M®. O ften these cell types are considered to  be 
totally different cells. However, the differences between 
MoDC and AaM® are n o t th a t large, since m onocyte 
derived m acrophages are cultured in  the presence o f  GM- 
CSF by som e groups [36] and  b o th  cells require the pres­
ence o f IL-4 or IL-13. Penna and co workers dem onstrated 
th a t several in vivo DC subtypes were n o t able to produce 
CCL18 [37], w hich is in  contrast w ith previous findings, 
w here CCL18 mRNA expression was found on  CD11c+ 
m yeloid b lood  DC [27]. Moreover, in vitro cultured 
MoDC have been identified as po ten t CCL18 producers 
[18,19]. These data suggest tha t a CD 14+ m onocyte origin 
in  com bination w ith a stim ulation by IL-4/IL-13 is critical 
for CCL18 secretion. This hypothesis is strengthened our 
data, dem onstrating tha t non-adheren t m onocytes/m ac­
rophages were able to  produce CCL18 under the influence 
o f  IL-4. In addition, the synergistic effects o f IL-4/IL-13 
and IL-10 on  CCL18 secretion by freshly isolated m o n o ­
Page 6 of 12
(page number not for citation purposes)
BMC Immunology 2006, 7:23 http://www.biomedeentral.eom/1471 -2172/7/23
Figure 6
CCL18 p ro d u c tio n  by m o n o cy tes  upon stim u la tio n  w ith  RA synovial fluid. Panel A. Monocytes/macrophages were 
cultured for three days. A part of the cells were incubated with IL-I0, IL-4 or IL-I3 alone (left side of the figure) and another 
part was incubated with these cytokines in the presence of RA SF (right side of the figure). Half of the latter were also incu­
bated with neutralizing antibodies against IL-I0 and IL-I3 o r both, which is shown by the white, gray and checked bars respec­
tively in panel A. The bars represent the mean CCLI8 pg/ml from 6 separate experiments. ND = not detectable. Panel B. The 
cells were then washed and only the cytokines were added again to  the fresh medium. After another 3 days, supernatant was 
measured again. The left side of the figure shows the CCLI8 production upon stimulation with IL-4, IL-I3 and IL-I0. The right 
side shows the production upon stimulation with these cytokines by cells that have been pre-incubated with SF for three days, 
in the presence or absence of anti IL-I0, anti IL-I3 or both (white, gray and checked bars respectively). ND = not detectable. * 
represents a p-value of <0,05 (Wilcoxon Signed Rank test). Panel C. The potency of neutralizing antibodies against IL-I3 and 
IL-I0 was tested by investigating their ability to  inhibit the synergy between IL-I3 and IL-I0 and IL-4 and IL-I0. The bars repre­
sent the mean (± SEM) CCLI8 secretion (pg/ml).
cytes were already clearly visible after 24 hours. This indi­
cates th a t a full differentiation in to  DC or M® is no t 
essential for CCL18 production  as has been suggested pre­
viously for CCL18 mRNA expression [16]. Thus m o n o ­
cytes rapidly secrete CCL18 u p o n  triggering with the right 
stimuli.
In the literature there is still som e controversy regarding 
the effect o f DC m aturation  on  CCL18 production. Vul-
cano and co workers suggested tha t DC dow n regulate 
their CCL18 secretion u p o n  m aturation [19]. This is in  
contrast w ith results from  other studies, where m aturation  
caused an  increased mRNA expression [10,26,27]. A sim ­
ilar contrast betw een protein  and  mRNA was found on 
b lood  DC [27,37]. The reason for these differences 
betw een mRNA expression and protein  secretion patterns 
still needs to  be investigated in  detail. Recently, we already 
provided evidence tha t DC m aturation  does n o t influence
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CCL18 protein  secretion [18], which is further strength­
ened by the data from  the present study, in  w hich differ­
en t TLR stim ulatory pathways did n o t induce CCL18 
production, whereas full DC m aturation  was achieved 
[31]. Also TNF-a and CD40L, bo th  well appreciated 
inducers o f DC m aturation  [38,39], d id  n o t enhance 
CCL18 production. Perhaps the discrepancy betw een the 
different reports is h idden  in  subtle differences in  culture 
conditions, w hich are difficult to  trace in  the published 
data. Intriguingly, stim ulation w ith IL-10 alone only lead 
to  a m arginal induction  o f  CCL18 secretion by m o n o ­
cytes/macrophages, b u t did act in  a strong synergy w ith IL-
4 or IL-13. The latter is n o t caused by an  up  regulation of 
the receptors IL-10Ra, IL-4Ra or IL-13Ra2 (data n o t 
shown). Probably intracellular pathways direct the syn­
ergy betw een these cytokines, w hich is an interesting topic 
tha t warrants further investigation.
We showed th a t RA SF induces CCL18 production  and 
strongly synergizes w ith IL-4, IL-13 and IL-10. Blocking 
studies revealed tha t neither IL-10 nor IL-13 in  SF were 
responsible for this effect. This suggests the presence of 
another, yet unidentified CCL18 inducing factor in  RA SF. 
A nother explanation for this fact m ight be the presence of 
inhibiting  factors in  SF th a t counter-regulate the effects of 
IL-10 and  IL-13. The identification o f the factor in  SF that 
drives the effects o n  CCL18 secretion may provide im por­
tan t new insights to  the pro-vs. anti inflam m atory balance 
in  RA. In order to  find this factor in  a com plex fluid like 
SF, m ore knowledge on  the pathways o f CCL18 regulation 
is critical. A nother intriguing observation from  our study 
is the finding tha t pre-incubation w ith SF lead to  a sus­
tained synergistic CCL18 secretion u p o n  stim ulation with 
IL-4, IL-13 and IL-10. This could be regarded as an 
"im printing effect", m eaning tha t the cell's previous envi­
ronm ent determ ines the nature o f response to  stimuli, 
even w hen the cell is no  longer in  such an  environm ent. 
Results from  previous studies, in  which we showed that 
m oD C from  RA patients differ in  phenotype and cytokine 
response from  control DC after 6 days in  culture m ight 
also be explained by such a phenom enon  [40,41].
U pon the encounter o f an antigen, DC norm ally m ature 
and migrate to  lym phoid  tissues in  order to  perform  their 
task o f antigen presentation to  T cells. Im m ature DC or 
M® can also encounter naïve T cells in  the periphery, 
w hich subsequently m ight result in  tolerance [42]. This 
peripheral tolerance is a critical m echanism  to prevent 
auto-im m unity. A role for CCL18 in  this part m ight 
explain the high expression o f CCL18 by alveolar M® 
[15,16], w hich are located at a site where the m aintenance 
o f tolerance to  non-pathogenic antigens, tha t are con­
stantly present, is crucial. Also the synergistic effect on  
CCL18 secretion tha t we found w ith IL-10, a cytokine that 
is well appreciated as a pivotal regulator o f  the im m une
system, fits in  this picture. The synovial lining in  the joints 
has similarities w ith the alveolar lining in  the lung. They 
b o th  consist o f M®-like cells and b o th  form  a barrier to  a 
site in  w hich self- and non-pathogenic antigens are con­
stantly present. The disease process in  RA is considered to 
be driven by pro inflam m atory cytokines such as IL-1 ß, 
TNF-a, IL-17 and  IL-18 [43-48], whereas CCL18 is regu­
lated by IL-10, IL-4 and  IL-13. It is therefore tem pting to 
speculate tha t the high CCL18 expression in  RA is 
designed to  u p ho ld  peripheral tolerance, which however 
seems to  fail. This failure m ight be explained in  two ways. 
The first explanation m ight be tha t the skewing in  the bal­
ance towards Th1 is still present despite the upregulation 
o f  anti inflam m atory mediators. Secondly, m ature DC are 
present in  the synovial tissue in  perivascular regions and 
secondary lym phoid organs [3,49], which is in  sharp con­
trast w ith healthy synovial tissue. Therefore an explana­
tion  for the ongoing im m une process m ight be th a t these 
m ature DC direct naïve T cells towards a phenotype tha t 
drives the pro-inflam m atory im m une response in  the syn­
ovial tissue.
Conclusion
In summary, we provide evidence tha t m onocyte derived 
cells produce CCL18 under the influence o f IL-4 and IL- 
13. IL-10 acts in  strong synergy w ith IL-4 and  IL-13 as a 
key regulator o f  CCL18 production by monocytes, which 
indicates tha t CCL18 secretion is n o t confined to  fully 
developed DC and  M®. In addition, the effects o f IL-4, IL- 
13 and IL-10 are strongly enhanced by RASF, w hich is due 
to  yet unidentified factors. Both the in vivo expression pat­
tern and the contributing factors to its regulation in vitro 
are suggestive for a role for CCL18 in  the regulation o f the 
im m une system, b o th  in  health  and  auto-im m une dis­
eases such as RA.
Methods
Patients and samples
For cell culture experiments, 50 m l peripheral b lood  was 
taken from  healthy volunteers and RA patients after 
receiving inform ed consent in  10 m l lith ium  heparine 
(Vacutainer, USA) tubes. Synovial biopsies from  RA 
patients were taken w ith small needle arthroscopy (Storz, 
Tutlingen, Germany). Synovial fluid from  RA patients was 
obtained during arthroscopy. For our experiments in  
w hich m onocytes were stim ulated w ith SF, a pool o f  SF 
from  10 different RA patients was used. Synovial samples 
from  healthy controls were taken during scheduled 
arthroscopic procedures by orthopedic surgeons in  
patients w ith traum atic knee injuries. The Nijm egen m ed­
ical ethics com m ittee (MEC) approved these studies.
Recom binant proteins and antibodies
For stim ulation o f iDC, we used 20 ng/m l recom binant 
(rh) IL-1ß, rhTNF-a, rhIL-10, rhIL-13, rhIL-15, rhIL-17,
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rhIL18, 10 ng/m l IFN-y (all R&D systems, M inneapolis, 
USA), o r 20 ng/m l RANKL and  CD40L (Pepro Tech, Rocky 
Hill, USA). DCs were cultured w ith 500 U /m l IL-4 and 
800 U /m l GM-CSF. The same IL-4 concentration was used 
for m onocyte stim ulations. For Toll-like receptor stim ula­
tion, 10 Mg/ml pam 3cys (TLR2), 25 Mg/ml poly (i:c) 
(TLR3), 2 Mg/ml lipopolysacharide (LPS) (TLR4), or 1 Mg/ 
m l R848 (TLR7/8) was used [31]. Blockade o f  IL-10 (Ebi- 
oscience, San Diego, USA) and blockade o f IL-13 (Dia- 
clone, Becanson, France) was achieved w ith a 1000x 
excess o f  a neutralizing antibody. For FACS analysis, we 
used m ouse-anti hum an  antibodies against CD14, (Dako, 
Glostrup, Denm ark), CD83 (Beckman Coulter, Mijdrecht, 
The N etherlands), IL-4Ra (Santa Cruz, California USA), 
IL-13Ra II (R&D systems, M inneapolis, USA) and  IL- 
10Ra (R&D systems, M inneapolis, USA) or mouse-iso- 
type control (goat IgG for IL-13RaII). For ELISA, m ouse 
anti-hum an and  biotynilated goat anti-hum an CCL18 
were used as capture and detection antibody (R&D sys­
tems, M inneapolis, USA). A standard curve was m ade 
w ith rhCCL18 (R&D systems, M inneapolis, USA). 
Im m uno histochem istry for CCL18 was perform ed w ith 
AZN-CK18B [18] as a prim ary antibody.
M onocyte/m acrophage and M o D C  isolation and culture
MoDC were cultured using essentially the same protocol 
as described previously [13,40]. In brief, peripheral b lood  
m ononuclear cells were isolated from  venous b lood  by 
density gradient centrifugation over Ficoll-Hypaque 
(Amersham Biosciences, Roosendaal, The N etherlands). 
The interphase was collected and  washed w ith citrated 
phosphate buffered saline, and  the cells were allowed to 
adhere for 1 ho u r at 37°C  in  RPMI-1640 (Life Technolo­
gies, Breda, The Netherlands) supplem ented w ith 2% 
hum an  serum  in  culture plates (Costar, Badhoeverdorp, 
The Netherlands). A dherent cells were cultured in  RPMI- 
1640 D utch m odification supplem ented w ith 10% fetal 
calf serum L-glutamine (Life Technologies, Breda, The 
Netherlands) and antibiotic-antim ycotic agents (Life 
Technologies, Breda, The N etherlands) (culture m edium ) 
in  the presence o f IL-4 (500 U/m l; Strathm ann Biotech, 
H am burg Germany) and  granulocyte m onocyte-colony 
stim ulating factor (GM-CSF) (800 U/m l; R&D systems, 
M inneapolis USA) for 6 days. Fresh culture m edium  w ith 
the same supplem ents was added at day 3, and then  iDC 
were harvested at day 6. To generate m ature DC, im m a­
ture DC were re-suspended in  a concentration o f 0,5 x 
106/m l in  fresh IL-4 and GM-CSF containing culture 
m edium . Im m ature DC were then  stim ulated w ith 
cytokines or m aturation  stim uli in  the presence o f IL-4 
and GM-CSF. DC were harvested after another 48 hours of 
culture. For CCL18 m easurem ents in  supernatant o f cells 
stim ulated w ith TLR ligands, aliquoted culture superna­
tan t from  previous experim ents was used [31].
For the culture o f monocytes/m acrophages, CD14+ cells 
were isolated w ith m agnetic cell sorting and separation 
(MACS). In brief, m ononuclear cells were labelled w ith 
anti CD14 m icrobeads (Miltenyi Biotec, Amsterdam, the 
N etherlands) and incubated for 30 m inutes at 4°C. CD14 
positive cells were then  separated from  the o ther cells 
using a MACS colum n (Miltenyi Biotec, Amsterdam, the 
Netherlands) according to the m anufacturers instructions. 
CD14+ cells were cultured in  a concentration o f 0,5 x 106 
cells/m l in  culture m edium  for up  to 6 days. W here appro­
priate, fresh culture m edium  was added on  day 3. After 6 
days, supernatant was collected for ELISA and cells were 
prepared for FACS analysis. In some additional experi­
m ents, m onocytes/m acrophages were cultured for three 
days in  the same concentration and in  the same m edia in  
teflon bags [34] or in  ro tation  discs (Cellon, Luxembourg) 
[35] to  prevent adherence o f  the cells. In experiments in  
w hich m onocytes/m acrophages were stim ulated w ith RA 
SF, the cells were cultured for three days in  the presence o f 
100 Ml RA SF. Cells were then  harvested and re-suspended 
in  fresh culture m edium  w ithou t SF, b u t w ith the 
cytokines tha t were present in  the first three days. Anti-IL- 
10 or anti-IL-13 neutralizing antibodies were only present 
during the first three days.
Immuno histochemistry
For im m uno histochemistry, frozen ST was cut in to  7 Mm 
sections and  m ounted  on  slides, air-dried, and  stored at - 
8 0 °C. Before staining, the cryosections were air-dried, 
fixed in  acetone for 10 m in  and  air-dried again. The sec­
tions were then  stained w ith 5 Mg/ml m ouse anti hum an  
CCL18 or isotype control a t 37°C  for 1 ho u r a t room  tem ­
perature (RT) and  washed in  PBS. Endogenous peroxidase 
was blocked w ith 0,3% H 2O 2/m ethanol. After another 
wash-step, the sections were incubated w ith a b iotin-con­
jugated horse anti-m ouse antibody at RT for 30 m in. Next, 
the samples were washed and incubated w ith avidin- 
biotin-HRP com plex (Vector, Burlingham, UK) at RT for 
20 m in. Next, the section were stained w ith diam inoden- 
zidine (DAB) (Sigma, Zwijndrecht, the Netherlands). 
Finally, sections were then  counterstained w ith hem atox­
ylin, rehydrated and m ounted  in  to  allow microscopic 
evaluation o f the samples.
Fluorescence-Activated Cell Sorter (FACS) analysis
The phenotype o f cells was characterized by using flow 
cytometry techniques (FACS). For this aim, cells were har­
vested and  collected by m eans o f centrifugation and  fur­
ther processed on  m elting ice. Cells were diluted in  buffer 
solution  (PBS w ith 1% bovine album ine, pH  7,4) in  a 
concentration o f 1.106 cells/m l and plated in  v-shaped 96 
wells plates (1.105 cells per plate). Cells were labeled w ith 
m onoclonal mouse- or goat anti hum an  antibodies or 
mouse-isotype control (goat IgG for IL-13RaII) and  incu­
bated  at a tem perature o f 4 °C  for 45 m inutes. Cells were
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then  washed and  labeled w ith goat-anti-m ouse (or rabbit 
anti-goat w hen appropriate) FITC (Zymed Laboratories, 
South San Francisco, USA) as a secondary antibody. After 
another 30 m inute incubation  at 4°C , cells were again 
washed, diluted in  buffer solution and  transferred into 
FACS tubes. Cells were gated according to  their forward 
and side scatters and fluorescence was m easured w ith a 
FACSCalibur® (Becton-Dickinson, San Jose, USA) and  Cel- 
lquest® software.
Enzyme Linked Immuno Sorbent Assay (ELISA)
For the detection o f  CCL18 protein levels o f  CCL18 in  
supernatant, a sandwich ELISA was perform ed as 
described previously [18,50]. In brief, maxisorb ELISA 
plates (Nunc, Roskilde, Denm ark) were coated overnight 
w ith 50 Ml/well 1 Mg/ml capture antibody in  PBS. Next, the 
plates were washed 3 times w ith PBS and  blocked w ith 
300 Ml 1% Bovine A lbum in (Sigma, Zwijndrecht, the 
Netherlands) in  PBS for a m in im um  o f 1 h  a t RT. After 
w ashing 3 tim es w ith ELISA wash buffer (PBS containing
0.05% Tween-20), the plates were incubated w ith 50 Ml/ 
well o f serial dilutions o f  the sam ple for 2 hrs at RT. Serial 
dilutions o f rhCCL18 were used to  obtain  a standard 
curve. After w ashing 3 tim es w ith ELISA wash buffer, the 
plates were incubated w ith 50 Ml/well o f 0.05 Mg/ml sec­
ondary antibody at RT for 1 hr. Thereafter, the plates were 
washed 3 tim es w ith ELISA wash buffer, and incubated 
w ith 50 Ml/well o f streptavidin conjugated to Poly-Horse 
Radish Peroxidase (CLB, Amsterdam) for 20 m inutes at 
RT. After washing 3 tim es w ith ELISA wash buffer, the 
presence o f HRP was detected using 50 Ml/well 3,3',5,5- 
tetram ethylbenzidine (TMB) (Biomerieux, Marcy l'Etoile, 
France) diluted in  peroxide buffer (UP) (Biomerieux, 
Marcy l'Etoile, France). The reaction was stopped w ith 50 
Ml/well 2,5M H 2SO4. Absorbance was m easured at 450 
nm  using a Magellan Tracker V4.XX (Tecan Austria 
GMBH). As an  internal control for inter-assay variability, 
a sam ple o f pooled  norm al hum an  serum (n  = 300) was 
taken along in  all assays. The m axim al accepted inter­
assay variability is 10%. The detection lim it o f  the ELISA 
is 100 pg/ml.
Statistical analysis
CCL18 production levels by m onocyte derived cells up o n  
different stim ulations were com pared w ith a W ilcoxon 
Signed Rank test. P-values < 0,05 were considered signifi­
cant.
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